Trump, Congress And The Future Of Value-Based Drug Contracting
CMS-driven experiments in value-based purchasing may slow in the new US administration but commercial pressures to price drugs according to their value will not.
You may also be interested in...
Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.
A combination of effective biopharma industry opposition as well as a poorly designed policy proposal probably doomed the drug pricing measure.
The promise of outcomes-based contracts for biopharmaceuticals has yet to be realized in the US. Although precise numbers are hard to come by, payers and manufacturers agree the field is still nascent. However, they don’t seem to be giving up on the idea.